Abigail Brooks, MA

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.

Treatment with DAA therapy at 3 years of age was associated with better health outcomes and cost savings versus deferring initiation to 6 years of age or older.

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

A greater patient-to-patient care technician ratio was associated with increased mortality and hospitalization with lower rates of waitlisting and transplantation among patients receiving in-center hemodialysis.

Baseline kidney function, AKD severity, and post-AKD kidney function were identified as important factors for predicting outcomes in patients with acute kidney injury requiring dialysis.

Findings reveal a 20% mortality rate in an Eastern European cohort, primarily due to cardiovascular diseases and linked to an absence of RASi use, among other factors.

Results of the systematic review point to significant evidence gaps in most cardiovascular risk management interventions for patients with CKD, especially those with stages 4 to 5.

Curative DAA therapy did not completely normalize immune activation and inflammatory biomarkers in individuals with a history of injection drug use and HCV infection.

Although abstinence is the safest approach, patients with SLD at low risk for advanced fibrosis can safely consume < 7.4 g/day of alcohol, equivalent to half of a standard US drinking unit.

Seropositivity was associated with greater albuminuria but not peripheral artery disease in a cohort of patients ≥ 50 years of age with type 2 diabetes mellitus.

Use of corticosteroids with supportive therapy reduced proteinuria but was associated with adverse effects and did not impact time to ESKD versus supportive therapy alone.

Our February 2024 month in review spotlights news in IgAN identification and management as well as recent research about various factors impacting renal care outcomes in different patient populations.

Results identified mesangial IgM deposition as an independent risk factor for ESKD in patients with IgAN, particularly in advanced disease stages.

Our February 2024 month in review highlights some of our top hepatology content from the past few weeks, including pipeline updates, phase 2/3 trial data, and new research in liver diseases.

Jairath discusses disease clearance and optimal treatment targeting in UC, highlighting what the ongoing VERDICT trial hopes to add to our understanding of improving patient outcomes.

Results showed 95.8% of patients who were treated for HCV with DAA therapy and underwent renal transplantation did not experience HCV recurrence.

Positive topline results show apraglutide outperformed placebo for relative change from baseline in actual weekly parenteral support volume at week 24 in adults with SBS-IF.

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.

Younger gestational age, lower birthweight, and a more severe initial AKI episode were identified as risk factors for recurrent AKI, which was linked to extended hospitalization.

Cross-sectional survey results suggest most providers are recommending HCV screening based on patient risk factors rather than universally for all patients 18-79 years of age.

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

All patients who received an HCV+ organ achieved SVR12 and had lower rates of rejection and chronic lung allograft dysfunction compared to uninfected donor organ recipients.

Zhang discusses the consequences of stigmatizing language for substance use disorders and reasons gastroenterologists and hepatologists may be falling behind.

Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.